Find 3 more new buyers similar to 
CNS Board
Randall Kaye , M.D. Background: Randall Kaye , MD serves as Chief Science Officer at SSI Strategy , a boutique consulting firm focused on Medical A...
Jul 17, 2020
Longboard Pharmaceuticals
2022-present (3 years)
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.
